Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Neuroradiology
Published in: Neuroradiology 3/2019

01-03-2019 | Retinoblastoma | Interventional Neuroradiology

Feasibility of intra-arterial chemotherapy for retinoblastoma: experiences in a large single center cohort study

Authors: Elena Stenzel, Sophia Göricke, Petra Temming, Eva Biewald, Stefan Zülow, Juliane Göbel, Isabel Wanke, Lale Umutlu, Christoph Kleinschnitz, Norbert Bornfeld, Michael Forsting, Alexander Radbruch, Christoph Mönninghoff

Published in: Neuroradiology | Issue 3/2019

Login to get access

Abstract

Purpose

In the last 10 years, intra-arterial chemotherapy (IAC) has been increasingly used in the clinical management of retinoblastoma. It is reported to provide tumor control even in advanced stage disease that might have previously required enucleation. In our clinical experience, there are three conditions that may impair the use of IAC: (1) significant collaterals to meningeal arteries, (2) technical failure of ophthalmic artery catheterization, or (3) retina blood supply from collaterals different to the ophthalmic artery. In the current study, we assessed the rate of IACs that could not be carried out in our institution due to these three reasons.

Methods

All patients admitted for IAC in our hospital were retrospectively assessed by chart review. Non-application rate of IAC was assessed and classified according to the three abovementioned criteria. Complication rate of both finalized and interrupted interventions was recorded.

Results

Ninety-eight patients (median age 21.4 months, range 5.3 months–10.5 years) were identified. IAC was performed in 69 (70.4%) patients and interrupted in 12 (12.2%) cases because of meningeal collaterals, in 8 (8.2%) because of technical failure to cannulate the ophthalmic artery, and in 9 (9.2%) because of alternative blood supply of the retina.

Conclusion

The rather defensive approach that is pursued in our center resulted in an overall non-application rate of IAC around 30%. The relatively high probability of conditions that impair the use of IAC needs to be addressed adequately in the patient conversation prior to the procedure. Our rate of 8% of abstention from IAC due to technical limitations might be reduced by the application of more rigorous therapeutic approaches such as balloon occlusion of the distal internal carotid artery. More research is finally needed to determine if IAC can be safely performed in the presence of meningeal collaterals and via branches of the external carotid artery.
Literature
1.
Kivela T (2009) The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol 93(9):1129–1131CrossRefPubMed
2.
Broaddus E, Topham A, Singh AD (2009) Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 93(1):24–27CrossRefPubMed
3.
Kaliki S, Shields CL, Rojanaporn D, al-Dahmash S, McLaughlin JP, Shields JA, Eagle RC Jr (2013) High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology 120(5):997–1003CrossRefPubMed
4.
Shields CL, Kaliki S, Al-Dahmash S et al (2013) Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation. Retina 33(10):2103–2109CrossRefPubMed
5.
Honavar SG, Singh AD, Shields CL et al (2002) Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 120(7):923–931CrossRefPubMed
6.
Mohney BG, Robertson DM, Schomberg PJ, Hodge DO (1998) Second nonocular tumors in survivors of heritable retinoblastoma and prior radiation therapy. Am J Ophthalmol 126(2):269–277CrossRefPubMed
7.
Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, Li FP, Fraumeni JF Jr (2005) Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 23(10):2272–2279CrossRefPubMed
8.
Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP (2008) A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 115(8):1398–1404 404 e1CrossRefPubMed
9.
Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH (2011) Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 129(6):732–737CrossRefPubMed
10.
Shields CL, Bianciotto CG, Jabbour P et al (2011) Intra-arterial chemotherapy for retinoblastoma: report no. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol 129(11):1399–1406CrossRefPubMed
11.
Shields CL, Manjandavida FP, Lally SE, Pieretti G, Arepalli SA, Caywood EH, Jabbour P, Shields JA (2014) Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology 121(7):1453–1460CrossRefPubMed
12.
13.
Shields CL, Lally SE, Leahey AM, Jabbour PM, Caywood EH, Schwendeman R, Shields JA (2014) Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol 25(5):374–385CrossRefPubMed
14.
Yamane T, Kaneko A, Mohri M (2004) The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 9(2):69–73CrossRefPubMed
15.
Suzuki S, Yamane T, Mohri M, Kaneko A (2011) Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology 118(10):2081–2087CrossRefPubMed
16.
Shields CL, Bianciotto CG, Jabbour P et al (2011) Intra-arterial chemotherapy for retinoblastoma: report no. 2, treatment complications. Arch Ophthalmol 129(11):1407–1415CrossRefPubMed
17.
Jabbour P, Chalouhi N, Tjoumakaris S et al (2012) Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma. J Neurosurg Pediatr 10(3):175–181CrossRefPubMed
18.
Chen JX, Alkire BC, Lam AC, Curry WT, Holbrook EH (2016) Aseptic meningitis with craniopharyngioma resection: consideration after endoscopic surgery. J Neurol Surg Rep 77(4):e151–e1e5CrossRefPubMedPubMedCentral
19.
Kaufman HH, Carmel PW (1978) Aseptic meningitis and hydrocephalus after posterior fossa surgery. Acta Neurochir 44(3–4):179–196CrossRefPubMed
20.
Yelehe-Okouma M, Czmil-Garon J, Pape E, Petitpain N, Gillet P (2018) Drug-induced aseptic meningitis: a mini-review. Fundam Clin Pharmacol 32(3):252–260CrossRefPubMed
21.
Sugiyama S, Iwai T, Oguri S, Koizumi T, Mitsudo K, Tohnai I (2017) Facial nerve paralysis after super-selective intra-arterial chemotherapy for oral cancer. Int J Oral Maxillofac Surg 46(6):682–686CrossRefPubMed
22.
Jang SY, Kim DJ, Kim CY, Wu CZ, Yoon JS, Lee SY (2014) Neoadjuvant intra-arterial chemotherapy in patients with primary lacrimal adenoid cystic carcinoma. Cancer Imaging 14:19PubMedPubMedCentral
23.
Takanami T, Kondo K, Asakage T (2009) Facial paralysis after superselective intra-arterial chemotherapy via the middle meningeal artery in maxillary cancer. Auris Nasus Larynx 36(4):479–481CrossRefPubMed
24.
Klufas MA, Gobin YP, Marr B, Brodie SE, Dunkel IJ, Abramson DH (2012) Intra-arterial chemotherapy as a treatment for intraocular retinoblastoma: alternatives to direct ophthalmic artery catheterization. AJNR Am J Neuroradiol 33(8):1608–1614CrossRefPubMed
25.
Bertelli E, Leonini S, Galimberti D, Moretti S, Tinturini R, Hadjistilianou T, de Francesco S, Romano DG, Vallone IM, Cioni S, Gennari P, Galluzzi P, Grazzini I, Rossi S, Bracco S (2016) Hemodynamic and anatomic variations require an adaptable approach during intra-arterial chemotherapy for intraocular retinoblastoma: alternative routes, strategies, and follow-up. AJNR Am J Neuroradiol 37(7):1289–1295CrossRefPubMed
26.
Kato MA, Green N, O’Connell K, Till SD, Kramer DJ, al-Khelaifi M, Han JH, Pryor KO, Gobin YP, Proekt A (2015) A retrospective analysis of severe intraoperative respiratory compliance changes during ophthalmic arterial chemosurgery for retinoblastoma. Paediatr Anaesth 25(6):595–602CrossRefPubMed
Metadata
Title
Feasibility of intra-arterial chemotherapy for retinoblastoma: experiences in a large single center cohort study
Authors
Elena Stenzel
Sophia Göricke
Petra Temming
Eva Biewald
Stefan Zülow
Juliane Göbel
Isabel Wanke
Lale Umutlu
Christoph Kleinschnitz
Norbert Bornfeld
Michael Forsting
Alexander Radbruch
Christoph Mönninghoff
Publication date
01-03-2019
Publisher
Springer Berlin Heidelberg
Published in
Neuroradiology / Issue 3/2019
Print ISSN: 0028-3940
Electronic ISSN: 1432-1920
DOI
https://doi.org/10.1007/s00234-019-02153-9

Other articles of this Issue 3/2019

Neuroradiology 3/2019 Go to the issue

Paediatric Neuroradiology

Post-contrast T1-weighted spine 3T MRI in children using a golden-angle radial acquisition

Diagnostic Neuroradiology

Filtered back projection revisited in low-kilovolt computed tomography angiography: sharp filter kernel enhances visualization of the artery of Adamkiewicz

Diagnostic Neuroradiology

Perfusion magnetic resonance imaging in differentiation of neurocysticercosis and tuberculoma

Diagnostic Neuroradiology

Optimization of 3D phase contrast venography for the assessment of the cranio-cervical venous system at 1.5 T

Diagnostic Neuroradiology

Variation of degree of stenosis quantification using different energy level with dual energy CT scanner

Spinal Neuroradiology

Differentiation between spinal cord diffuse midline glioma with histone H3 K27M mutation and wild type: comparative magnetic resonance imaging